Letter

Hormone replacement therapy may not always be right choice to prevent cardiovascular disease

BMJ 1996; 313 doi: 10.1136/bmj.313.7058.687 (Published 14 September 1996)
Cite this as: BMJ 1996;313:687.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Salvatore Panico, Senior researcher,
  2. Rocco Galasso, Researcher,
  3. Egidio Celentano, Researcher,
  4. Luisa Frova, Researcher,
  5. Riccardo Capocaccia, Senior researcher,
  6. Franco Berrino, Director
  1. Department of Clinical and Experimental Medicine, Federico II University, Medical School, 80131 Naples, Italy
  2. National Bureau of Statistics, 00100 Rome, Italy
  3. Istituto Superiore di Sanita, 00191 Rome, Italy
  4. Division of Epidemiology, National Cancer Institute, 20133 Milan, Italy

    EDITOR,—Hormone replacement therapy in postmenopausal women has been shown to have an overall benefit on mortality.1 2 None of the studies, however, were carried out in countries with a low frequency of ischaemic heart disease; nor were trends in mortality taken into account.

    We performed a risk-benefit analysis of the effect of hormone replacement therapy on mortality from ischaemic heart disease, breast cancer, stroke, and endometrial cancer in postmenopausal women. Reference mortalities were estimated for successive birth cohorts of Italian women by age range, and a …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular